← Bioventus Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Net sales | $340.1m |
$321.2m
-5.58%
|
$430.9m
+34.17%
|
$512.1m
+18.85%
|
$512.3m
+0.04%
|
$573.3m
+11.89%
|
$568.1m
-0.91%
|
$581.8m
+2.42%
|
|
| Cost of sales (including depreciation and amortization of $41,251, $41,882 and $48,503, respectively) | $90.9m |
$87.6m
-3.62%
|
$128.2m
+46.27%
|
$181.0m
+41.22%
|
$184.2m
+1.72%
|
$185.1m
+0.49%
|
$179.9m
-2.77%
|
— | |
| Gross profit | $249.2m |
$233.5m
-6.29%
|
$302.7m
+29.63%
|
$331.1m
+9.37%
|
$328.2m
-0.87%
|
$388.2m
+18.29%
|
$388.2m
-0.02%
|
$399.4m
+2.91%
|
|
| Research and development expense | $11.1m | $11.2m | $19.0m | $25.9m | $13.4m | $13.6m | $12.1m | $11.6m | |
| Selling, general and administrative expense | $198.5m | $193.1m | $254.3m | $332.6m | $303.9m | $340.9m | $314.0m | $322.5m | |
| Restructuring costs | $575k | $563k | $2.5m | $6.8m | $840k | ($52k) | $2.2m | — | |
| Operating income (loss) | $31.2m |
$21.2m
-31.92%
|
$12.1m
-43.21%
|
($251.0m)
-2181.49%
|
($81.7m)
+67.45%
|
($12.0m)
+85.34%
|
$54.0m
+550.58%
|
$60.6m
+12.19%
|
|
| Interest expense, net | $21.6m | $9.8m | $1.1m | $25.8m | $40.7m | $38.8m | $26.5m | $19.9m | |
| Change in prior service cost and unrecognized gain (loss) for defined benefit plan adjustment | ($78k) | ($54k) | $60k | $133k | ($8k) | $13k | $21k | — | |
| Other expense (income) | $21.5m | $5.3m | $4.4m | $12.9m | $39.4m | $37.1m | $28.3m | — | |
| Income (loss) before income taxes | $9.7m | $15.9m | $7.6m | ($263.9m) | ($121.1m) | ($49.1m) | $25.7m | — | |
| Income tax (benefit) expense, net | $1.6m | $1.2m | ($2.0m) | ($50.5m) | $85k | ($5.3m) | ($1.6m) | — | |
| Net income (loss) from continuing operations | $8.1m | $14.7m | $9.6m | ($144.7m) | ($121.2m) | ($43.8m) | $27.3m | $54.5m | |
| Net income (loss) | $6.3m |
$14.7m
+133.76%
|
$9.6m
-34.89%
|
($213.4m)
-2326.07%
|
($195.6m)
+8.33%
|
($43.8m)
+77.59%
|
$27.3m
+162.22%
|
$54.5m
+99.69%
|
|
| Net income (loss) attributable to Bioventus Inc. | $6.9m | $16.4m | $19.4m | ($158.7m) | ($156.2m) | ($33.5m) | $22.7m | $54.5m | |
| Continuing operations, basic (in dollars per share) | — | — | ($0.11) | ($1.70) | ($1.54) | ($0.52) | $0.34 | — | |
| Discontinued operations, basic (in dollars per share) | — | — | ($0.04) | ($0.89) | ($0.95) | $0.00 | $0.00 | — | |
| Basic income (loss) per Class A common stock (in dollars per share) | — | — | ($0.15) | ($2.59) | ($2.49) | ($0.52) | $0.34 | — | |
| Continuing operations, diluted (in dollars per share) | — | — | ($0.11) | ($1.70) | ($1.54) | ($0.52) | $0.33 | — | |
| Discontinued operations, diluted (in dollars per share) | — | — | ($0.04) | ($0.89) | ($0.95) | $0.00 | $0.00 | — | |
| Diluted income (loss) per Class A common stock (in dollars per share) | — | — | ($0.15) | ($2.59) | ($2.49) | ($0.52) | $0.33 | — | |
| Basic (in shares) | — | — | $45.5m | $61.4m | $62.6m | $64.5m | $66.6m | $67.3m | |
| Diluted (in shares) | — | — | $45.5m | $61.4m | $62.6m | $64.5m | $68.9m | $69.7m | |
| Change in fair value of contingent consideration | $0 | $0 | $829k | $6.5m | $719k | $1.4m | $0 | — | |
| Depreciation and amortization | $7.9m | $7.4m | $8.4m | $21.2m | $8.8m | $7.7m | $5.7m | $4.8m | |
| Impairment of assets | — | — | $0 | $0 | $78.6m | $36.4m | $0 | — | |
| Loss on disposals | — | — | $0 | $0 | $3.6m | $292k | $81k | — | |
| Loss on extinguishment | — | — | — | — | $0 | $0 | $326k | — | |
| Loss from discontinued operations, net of tax | $1.8m | $0 | $0 | ($68.7m) | ($74.4m) | $0 | $0 | — | |
| (Income) loss attributable to noncontrolling interest - continuing operations | — | — | $9.8m | $40.7m | $24.5m | $10.3m | ($4.5m) | — | |
| Loss attributable to noncontrolling interest - discontinued operations | — | — | $0 | $14.0m | $14.9m | $0 | $0 | — | |
| Change in foreign currency translation adjustments | ($322k) | $2.1m | ($1.3m) | ($501k) | $1.1m | ($4.2m) | $1.8m | — | |
| Change in the fair value of cash flow hedges | — | — | — | — | $0 | $0 | ($991k) | — | |
| Comprehensive income (loss) | $5.9m | $16.8m | $8.3m | ($213.8m) | ($194.5m) | ($48.0m) | $28.1m | — | |
| Comprehensive (income) loss attributable to noncontrolling interest - continuing operations | — | — | $9.8m | $40.8m | $24.2m | $11.1m | ($4.7m) | — | |
| Comprehensive income (loss) attributable to Bioventus Inc. | $6.5m | $18.5m | $18.1m | ($159.0m) | ($155.3m) | ($36.9m) | $23.4m | — |